Cargando…

Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus

The humoral immune system responds to chronic hepatitis C virus (HCV) infection by producing neutralising antibodies (nAb). In this study we generated three HCV pseudoparticles in which E1E2 glycoprotein sequence was targeted by the host humoral immune system. We used patient derived virus free Fabs...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Amruta S., Owsianka, Ania, Palmer, Brendan A., O’Halloran, Ciaran J., Walsh, Nicole, Crosbie, Orla, Kenny-Walsh, Elizabeth, Patel, Arvind H., Fanning, Liam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448734/
https://www.ncbi.nlm.nih.gov/pubmed/28558001
http://dx.doi.org/10.1371/journal.pone.0175349
_version_ 1783239614173020160
author Naik, Amruta S.
Owsianka, Ania
Palmer, Brendan A.
O’Halloran, Ciaran J.
Walsh, Nicole
Crosbie, Orla
Kenny-Walsh, Elizabeth
Patel, Arvind H.
Fanning, Liam J.
author_facet Naik, Amruta S.
Owsianka, Ania
Palmer, Brendan A.
O’Halloran, Ciaran J.
Walsh, Nicole
Crosbie, Orla
Kenny-Walsh, Elizabeth
Patel, Arvind H.
Fanning, Liam J.
author_sort Naik, Amruta S.
collection PubMed
description The humoral immune system responds to chronic hepatitis C virus (HCV) infection by producing neutralising antibodies (nAb). In this study we generated three HCV pseudoparticles in which E1E2 glycoprotein sequence was targeted by the host humoral immune system. We used patient derived virus free Fabs (VF-Fabs) obtained from HCV genotype 1a (n = 3), genotype 1b (n = 7) and genotype 3a (n = 1) for neutralisation of HCVpp produced in this study both individually and in combination. Based on the available anti-HCV monoclonal nAb mapping information we selected amino acid region 384–619 for conformational epitope mapping. Amongst our notable findings, we observed significant reduction in HCVpp infectivity (p<0.05) when challenged with a combination of inter genotype and subtype VF-Fabs. We also identified five binding motifs targeted by patient derived VF-Fab upon peptide mapping, of which two shared the residues with previously reported epitopes. One epitope lies within an immunodominant HVR1 and two were novel. In summary, we used a reverse epitope mapping strategy to identify preferred epitopes by the host humoral immune system. Additionally, we have combined different VF-Fabs to further reduce the HCVpp infectivity. Our data indicates that combining the antigen specificity of antibodies may be a useful strategy to reduce (in-vitro) infectivity.
format Online
Article
Text
id pubmed-5448734
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-54487342017-06-15 Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus Naik, Amruta S. Owsianka, Ania Palmer, Brendan A. O’Halloran, Ciaran J. Walsh, Nicole Crosbie, Orla Kenny-Walsh, Elizabeth Patel, Arvind H. Fanning, Liam J. PLoS One Research Article The humoral immune system responds to chronic hepatitis C virus (HCV) infection by producing neutralising antibodies (nAb). In this study we generated three HCV pseudoparticles in which E1E2 glycoprotein sequence was targeted by the host humoral immune system. We used patient derived virus free Fabs (VF-Fabs) obtained from HCV genotype 1a (n = 3), genotype 1b (n = 7) and genotype 3a (n = 1) for neutralisation of HCVpp produced in this study both individually and in combination. Based on the available anti-HCV monoclonal nAb mapping information we selected amino acid region 384–619 for conformational epitope mapping. Amongst our notable findings, we observed significant reduction in HCVpp infectivity (p<0.05) when challenged with a combination of inter genotype and subtype VF-Fabs. We also identified five binding motifs targeted by patient derived VF-Fab upon peptide mapping, of which two shared the residues with previously reported epitopes. One epitope lies within an immunodominant HVR1 and two were novel. In summary, we used a reverse epitope mapping strategy to identify preferred epitopes by the host humoral immune system. Additionally, we have combined different VF-Fabs to further reduce the HCVpp infectivity. Our data indicates that combining the antigen specificity of antibodies may be a useful strategy to reduce (in-vitro) infectivity. Public Library of Science 2017-05-30 /pmc/articles/PMC5448734/ /pubmed/28558001 http://dx.doi.org/10.1371/journal.pone.0175349 Text en © 2017 Naik et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Naik, Amruta S.
Owsianka, Ania
Palmer, Brendan A.
O’Halloran, Ciaran J.
Walsh, Nicole
Crosbie, Orla
Kenny-Walsh, Elizabeth
Patel, Arvind H.
Fanning, Liam J.
Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus
title Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus
title_full Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus
title_fullStr Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus
title_full_unstemmed Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus
title_short Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus
title_sort reverse epitope mapping of the e2 glycoprotein in antibody associated hepatitis c virus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448734/
https://www.ncbi.nlm.nih.gov/pubmed/28558001
http://dx.doi.org/10.1371/journal.pone.0175349
work_keys_str_mv AT naikamrutas reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT owsiankaania reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT palmerbrendana reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT ohalloranciaranj reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT walshnicole reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT crosbieorla reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT kennywalshelizabeth reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT patelarvindh reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus
AT fanningliamj reverseepitopemappingofthee2glycoproteininantibodyassociatedhepatitiscvirus